Yahoo Finance • 8 days ago
Shares of Scholar Rock tumbled Tuesday after the FDA rejected the company's spinal muscular atrophy drug, citing concerns at a plant. Continue Reading Ver comentarios... Full story
Yahoo Finance • 8 days ago
No other approvability issues cited in CRL Scholar Rock intends to resubmit the apitegromab Biologics License Application (BLA) upon resolution of Catalent Indiana LLC-related observations CAMBRIDGE, Mass., September 23, 2025--(BUSINESS... Full story
Yahoo Finance • last month
We recently published 10 Big Names With Surprising Gains. Scholar Rock Holding Corp. (NASDAQ:SRRK) is one of Wednesday’s best performers. Scholar Rock saw its share prices jump by 14.26 percent on Wednesday to close at $34.4 apiece as inv... Full story
Yahoo Finance • last month
Investing.com - Jefferies has initiated coverage on Scholar Rock (NASDAQ:SRRK) with a Buy rating and a price target of $50.00, according to a research note released Thursday. The company, currently valued at $3.3 billion, has received stro... Full story
Yahoo Finance • last month
[graph from neons 1] Jonathan Kitchen * An update from Regeneron Pharmaceuticals (NASDAQ:REGN [https://seekingalpha.com/symbol/REGN]) earlier Wednesday regarding [https://seekingalpha.com/news/4487554-regenerons-eylea-injection-review-d... Full story
Yahoo Finance • 2 months ago
Scholar Rock Holding Corp (SRRK) reported its second-quarter 2025 earnings, revealing an EPS of -0.98, which fell short of the anticipated -0.66, marking a 48.48% negative surprise. This led to a premarket stock price decline of 14.44%, wi... Full story
Yahoo Finance • 2 months ago
SCHOLAR ROCK HOLDING CORP (NASDAQ:SRRK [https://www.chartmill.com/stock/quote/SRRK]) REPORTS Q2 2025 RESULTS: WIDER LOSS THAN EXPECTED, MARKET REACTS POSITIVELY Scholar Rock Holding Corp posted a net loss of $110 million, or $0.98 per sha... Full story
Yahoo Finance • 2 months ago
FDA accepted the apitegromab BLA under priority review with a PDUFA target action of September 22, 2025; finalizing U.S. commercial launch preparations European Medicines Agency validatedMarketing Authorisation Application (MAA), and regu... Full story
Yahoo Finance • 3 months ago
Mo Qatanani, Chief Scientific Officer of Scholar Rock Holding Corp (NASDAQ:SRRK), sold 24,066 shares of common stock on July 8, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The company, currently valued... Full story
Yahoo Finance • 3 months ago
Introduction & Market Context Scholar Rock Holding Corp (NASDAQ:SRRK) presented its Q1 2025 Business Update on May 14, highlighting significant progress toward the potential launch of its lead candidate apitegromab for Spinal Muscular At... Full story
Yahoo Finance • 3 months ago
Wall Street’s major market averages seesawed back and forth on Friday and finished mixed as Federal Reserve Governor Christopher Waller hinted at potential rate cuts in July. The S&P 500 Health Care Index Sector (NYSEARCA:XLV [https://see... Full story
Yahoo Finance • 3 months ago
By Bhanvi Satija (Reuters) -Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo Nordisk could generate more than $30 billion in sales by 2035, analysts at TD Cowen said... Full story
Yahoo Finance • 3 months ago
Friday’s trading session is showcasing a mix of retreats and advances across the stock market, with mega-cap and large-cap stocks experiencing notable intra-day movements. From tech giants to pharmaceutical leaders, the market is reacting... Full story
Yahoo Finance • 3 months ago
Check out the companies making headlines in midday trading: Steel stocks — Shares of steel producer Nucor jumped more than 3%. The company issued rosy guidance for its second-quarter earnings, calling for $2.55 to $2.65 per share, while Fa... Full story
Yahoo Finance • 3 months ago
Wednesday’s trading session is showcasing significant movements across various market cap categories, with stocks like Oracle Corp (NYSE:ORCL) and JP Morgan Chase (NYSE:JPM) leading the gains in the mega-cap space, while Regencell Bios... Full story
Yahoo Finance • 3 months ago
[Two injectors dosing pens for subcutaneous injection of antidiabetic medication or anti-obesity medication hovering over a blue background. Yellow measuring tape around the injectors.] Alones Creative Scholar Rock (NASDAQ:SRRK [https://s... Full story
Yahoo Finance • 4 months ago
Jefferies has identified several biotechnology companies as promising merger and acquisition targets, highlighting firms with de-risked or commercial-stage assets that could generate significant sales. In a recent research note, the firm s... Full story
Yahoo Finance • 2 years ago
Edward Myles, COO & CFO of Scholar Rock Holding Corp (NASDAQ:SRRK), sold 6,634 shares of the company on January 16, 2024, according to a recent SEC filing. The transaction was executed at an average price of $15.93 per share, resulting in... Full story
Yahoo Finance • 3 years ago
- Enrollment of pivotal Phase 3 SAPPHIRE trial evaluating apitegromab on track for completion in 2023, and 36-month extension data from Phase 2 TOPAZ trial expected in mid-2023 - Phase 1 DRAGON trial of SRK-181 continues to advance with b... Full story
Yahoo Finance • 3 years ago
- Tertiary endpoint data show trends of continuous improvement in activities of daily living, fatigue, and endurance over 24 months - These data indicate the potential for sustained improvement in quality-of-life measures for patients wit... Full story